Aim: To determine if a 2-weeks pre-operative course of fluorometholone (FML) eyedrops in chronically medicated glaucoma patients reduces pro-inflammatory cytokines levels pre-operatively and improves early post-operative outcomes after trabeculectomy or phaco-trabeculectomy.
Methods: Asingle-center, unmasked, prospective pilot interventional case series of 36 FML-pretreated glaucoma patients, who received a 2-week pre-operative course of FML eyedrops, and 307 glaucoma patients without FML pre-treatment on chronic IOP-lowering topical medications undergoing trabeculectomy or phaco-trabeculectomy. Multiplex bead assay was used to quantify the presence of pro-inflammatory cytokines in tear samples before and after the use of FML eyedrops, prior to surgery. Clinical outcome measures of post-operative outcomes included IOP and additional post-operative interventions (i.e. needling, glaucoma medications and surgery) required to achieve desired IOP at 6 months.
Results: After excluding patients with a low MCP-1 level (<250pg/ml/mg) at baseline, propensity score matched analysis showed that the mean age for the FML group (n=17) was 71.88 years and the non FML group (n=17) was 73.71 years (p=0.449). The mean duration of glaucoma medications used pre-operatively was 31.29 months (FML group) and 34.79 months (non-FML group) (p=0.763). Patients with FML treatment had a lower odds of requiring any post-operative intervention (including needling, surgery or IOP-lowering medications) (OR 0.22, CI 0.049-0.95, p=0.042) compared to patients who did not have pre-operative FML treatment.
Conclusions: In patients with higher levels of MCP-1 pre-operatively, the use of FML for 2 weeks pre-operatively improved their early post-operative outcomes following trabeculectomy or phaco-trabeculectomy.